AbCellera Biologics Inc. (ABCL) intrinsic value & 10-year financials
AbCellera Biologics Inc. (ABCL) has a Graham intrinsic value of $16.61 per share. At $11.80 on Oct 17, 2026, the stock trades 29% below that value. Over the last 8 fiscal years revenue grew 36.5% a year to $75.1M, with an average return on invested capital of 2.7%.
- Graham intrinsic value
- $16.61
- Share price (Oct 17, 2026)
- $11.80
- Price vs Graham value
- 29% below
- Market cap
- $3.5B
- Revenue (FY2025)
- $75.1M
- Revenue growth (8-yr CAGR)
- 36.5%
- ROIC (10-yr avg)
- 2.7%
- Free cash flow (FY2025)
- -$174.1M
ABCL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $75.1M | -$146.4M | -$0.49 | -$174.1M | -289.0% | -18.5% |
| FY2024 | $28.8M | -$162.9M | -$0.55 | -$187.0M | -1091.7% | -24.9% |
| FY2023 | $38.0M | -$146.4M | -$0.51 | -$120.8M | -623.8% | -19.8% |
| FY2022 | $485.4M | $158.5M | $0.50 | $206.7M | 44.6% | 19.0% |
| FY2021 | $375.2M | $153.5M | $0.48 | $186.1M | 54.5% | 34.6% |
| FY2020 | $233.2M | $118.9M | $0.45 | $13.0M | 66.9% | 48.9% |
| FY2019 | $11.6M | -$2.2M | -$0.01 | -$1.3M | -35.5% | -20.2% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
AbCellera Biologics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
AbCellera Biologics Inc. has historically struggled to out-earn its cost of capital, averaging just 6.6% ROIC.
AbCellera Biologics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, AbCellera Biologics Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $16.61 per share.